Pain Medicine, Interventional Pain Medicine · San Antonio, TX
NPI
1255309084
Since 2006
Specialty
Pain Medicine, Interventional Pain Medicine
Code 208VP0014X
Group practices
1
Medicare group memberships
Hospitals
0
Hospital affiliations
3903 Wiseman Blvd Ste 101
San Antonio, TX, 78251
Phone (210) 615-1901
Groups this clinician bills Medicare through
Medicare paid, 2024
$963K
41,774 services
Medicare patients, 2024
529
Average age 72
Drug cost, 2024
$1.6M
13,205 prescriptions
Company payments, 2025
$1,164
From 10 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Sergio J Alvarado was code J1010 (injection, methylprednisolone acetate, 1 mg), 16,350 times for 217 patients. In total Sergio J Alvarado billed 41,774 services in 80 codes, and Medicare paid $963K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2025-08-25.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J1010 Injection, methylprednisolone acetate, 1 mg | Office | 16,350 | 217 | $0.10 | $1,653 |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 5,162 | 257 | $0.09 | $455 |
| 99214 Office E&M - Established | Office | 3,797 | 508 | $87.20 | $331K |
| J0131 Injection, acetaminophen, not otherwise specified,10 mg | Office | 1,802 | 19 | $0.04 | $67.93 |
| J3304 Injection, triamcinolone acetonide, preservative-free, extended-release, microsphere formulation, 1 mg | Office | 1,536 | 16 | $13.83 | $21K |
| 96138 Behavioral Health Services | Office | 1,114 | 276 | $25.34 | $28K |
| 96130 Behavioral Health Services | Office | 1,114 | 276 | $88.82 | $99K |
| 96132 Behavioral Health Services | Office | 1,113 | 276 | $98.30 | $109K |
| Q9967 Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | Office | 1,105 | 212 | $0.10 | $113 |
| G0396 Alcohol and/or substance (other than tobacco) misuse structured assessment (e.g., audit, dast), and brief intervention 15 to 30 minutes | Office | 1,101 | 276 | $26.25 | $29K |
| 80307 Drug Tests | Office | 1,043 | 333 | $59.68 | $62K |
| J3301 Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 359 | 88 | $0.69 | $249 |
| J1885 Injection, ketorolac tromethamine, per 15 mg | Office | 246 | 101 | $0.51 | $125 |
| G0480 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms | Office | 233 | 133 | $105.38 | $25K |
| 64483 Nerve Block Injection - Back | Office | 222 | 146 | $228.61 | $51K |
By year: 2022 $633K for 11,216 services; 2023 $733K for 19,308 services; 2024 $963K for 41,774 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 80307 Drug Tests | 1,043 | 333 | $59.68 | $62K |
| G0480 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms | 233 | 133 | $105.38 | $25K |
| G0482 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms | 112 | 82 | $187.98 | $21K |
| 82962 Clinical Chemistry | 65 | 48 | $3.21 | $209 |
| G0483 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms | 38 | 28 | $241.98 | $9,195 |
Medicare prescription drug claims, 2024
In 2024, the drug Sergio J Alvarado prescribed most often to Medicare patients was Hydrocodone-Acetaminophen (Hydrocodone/Acetaminophen), with 4,001 prescriptions and refills. In total Sergio J Alvarado wrote 13,205 Medicare prescriptions that cost $1.6M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | 4,001 | 4,025 | 411 | $142K |
| Gabapentin Generic | 792 | 850 | 116 | $9,420 |
| Tramadol Hcl Generic | 722 | 738 | 101 | $8,373 |
| Diclofenac Sodium Generic | 648 | 653 | 126 | $658K |
| Tizanidine Hcl Generic | 594 | 608 | 81 | $5,087 |
| Oxycodone Hcl Generic | 579 | 579 | 65 | $15K |
| Lidocaine Generic | 492 | 507 | 97 | $44K |
| Baclofen Generic | 468 | 482 | 73 | $5,414 |
| Morphine Sulfate Er Morphine Sulfate | 444 | 444 | 41 | $17K |
| Pregabalin Generic | 428 | 442 | 59 | $6,860 |
| Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen | 350 | 350 | 47 | $8,643 |
| Hydromorphone Hcl Generic | 334 | 334 | 35 | $13K |
| Cyclobenzaprine Hcl Generic | 332 | 348 | 53 | $2,590 |
| Diclofenac Epolamine Generic | 291 | 291 | 65 | $176K |
| Celecoxib Generic | 255 | 261 | 47 | $4,344 |
Brand drugs: 926 claims; generic drugs: 12,279 claims; opioid claims: 7,151.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Sergio J Alvarado $1,164 ($1,164 in general payments such as food, travel and fees) from 10 companies. The largest payer was Boston Scientific Corporation with $335.
| Company | Payments | Amount |
|---|---|---|
| Boston Scientific Corporation BSX | 9 | $335 |
| Globus Medical, Inc. GMED | 4 | $185 |
| Medtronic, Inc. MDT | 4 | $145 |
| Curonix LLC | 2 | $144 |
| Ferring Pharmaceuticals Inc. | 6 | $129 |
| Averitas Pharma Inc. | 4 | $94.84 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC BHC | 3 | $48.91 |
| Collegium Pharmaceutical, Inc. COLL | 2 | $31.74 |
| Vertex Pharmaceuticals Incorporated VRTX | 1 | $26.94 |
| Abbott Laboratories ABT | 1 | $23.16 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.